Expanding HER2 horizons: Implications for NSCLC and beyond

🔬 In-depth HER2 targeting discussion
Join us for an insightful discussion featuring two medical oncologists and a pathologist.
This activity covers:
Key considerations for tissue-agnostic HER2 targeting in solid tumours
Latest clinical trial data on both approved and emerging HER2-targeted therapies for NSCLC
Best practices for testing HER2 alterations in NSCLC
👉 Watch the full discussion here: touchoncologyi...
👉Or register to stay informed
touchoncology....
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.